Data as of May 22
| -0.24 / -5.58%|
The 6 analysts offering 12-month price forecasts for RTI Biologics Inc have a median target of 5.00, with a high estimate of 6.00 and a low estimate of 4.50. The median estimate represents a +23.15% increase from the last price of 4.06.
The current consensus among 7 polled investment analysts is to Buy stock in RTI Biologics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.